Dr. Divakaran is developing novel induced-proximity-based therapeutic modalities for targeted editing of the epigenome to silence the expression of common cancer-causing genes.
Development of a Targeted Epigenome Modification Platform
Momentum Fellow (2022-present)
Anand Divakaran, PhD, University of California, Berkeley
Anand Divakaran, PhD